• Je něco špatně v tomto záznamu ?

Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions

B. Vaňková, T. Vaněček, N. Ptáková, V. Hájková, M. Dušek, M. Michal, P. Švajdler, O. Daum, M. Daumová, M. Michal, R. Mezencev, M. Švajdler

. 2020 ; 59 (10) : 562-568. [pub] 20200610

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026512

Oncogenic gene fusions represent attractive targets for therapy of cancer. However, the frequency of actionable genomic rearrangements in colorectal cancer (CRC) is very low, and universal screening for these alterations seems to be impractical and costly. To address this problem, several large scale studies retrospectivelly showed that CRC with gene fusions are highly enriched in groups of tumors defined by MLH1 DNA mismatch repair protein deficiency (MLH1d), and hypermethylation of MLH1 promoter (MLH1ph), and/or the presence of microsatellite instability, and BRAF/KRAS wild-type status (BRAFwt/KRASwt). In this study, we used targeted next generation sequencing (NGS) to explore the occurence of potentially therapeutically targetable gene fusions in an unselected series of BRAFwt/KRASwt CRC cases that displayed MLH1d/MLH1ph. From the initially identified group of 173 MLH1d CRC cases, 141 cases (81.5%) displayed MLH1ph. BRAFwt/RASwt genotype was confirmed in 23 of 141 (~16%) of MLH1d/MLH1ph cases. Targeted NGS of these 23 cases identified oncogenic gene fusions in nine patients (39.1%; CI95: 20.5%-61.2%). Detected fusions involved NTRK (four cases), ALK (two cases), and BRAF genes (three cases). As a secondary outcome of NGS testing, we identified PIK3K-AKT-mTOR pathway alterations in two CRC cases, which displayed PIK3CA mutation. Altogether, 11 of 23 (~48%) MLH1d/MLH1ph/BRAFwt/RASwt tumors showed genetic alterations that could induce resistance to anti-EGFR therapy. Our study confirms that targeted NGS of MLH1d/MLH1ph and BRAFwt/RASwt CRCs could be a cost-effective strategy in detecting patients with potentially druggable oncogenic kinase fusions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026512
003      
CZ-PrNML
005      
20211026132837.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/gcc.22861 $2 doi
035    __
$a (PubMed)32427409
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vaňková, Bohuslava $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
245    10
$a Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions / $c B. Vaňková, T. Vaněček, N. Ptáková, V. Hájková, M. Dušek, M. Michal, P. Švajdler, O. Daum, M. Daumová, M. Michal, R. Mezencev, M. Švajdler
520    9_
$a Oncogenic gene fusions represent attractive targets for therapy of cancer. However, the frequency of actionable genomic rearrangements in colorectal cancer (CRC) is very low, and universal screening for these alterations seems to be impractical and costly. To address this problem, several large scale studies retrospectivelly showed that CRC with gene fusions are highly enriched in groups of tumors defined by MLH1 DNA mismatch repair protein deficiency (MLH1d), and hypermethylation of MLH1 promoter (MLH1ph), and/or the presence of microsatellite instability, and BRAF/KRAS wild-type status (BRAFwt/KRASwt). In this study, we used targeted next generation sequencing (NGS) to explore the occurence of potentially therapeutically targetable gene fusions in an unselected series of BRAFwt/KRASwt CRC cases that displayed MLH1d/MLH1ph. From the initially identified group of 173 MLH1d CRC cases, 141 cases (81.5%) displayed MLH1ph. BRAFwt/RASwt genotype was confirmed in 23 of 141 (~16%) of MLH1d/MLH1ph cases. Targeted NGS of these 23 cases identified oncogenic gene fusions in nine patients (39.1%; CI95: 20.5%-61.2%). Detected fusions involved NTRK (four cases), ALK (two cases), and BRAF genes (three cases). As a secondary outcome of NGS testing, we identified PIK3K-AKT-mTOR pathway alterations in two CRC cases, which displayed PIK3CA mutation. Altogether, 11 of 23 (~48%) MLH1d/MLH1ph/BRAFwt/RASwt tumors showed genetic alterations that could induce resistance to anti-EGFR therapy. Our study confirms that targeted NGS of MLH1d/MLH1ph and BRAFwt/RASwt CRCs could be a cost-effective strategy in detecting patients with potentially druggable oncogenic kinase fusions.
650    _2
$a adenokarcinom $x diagnóza $x genetika $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a anaplastická lymfomová kináza $x genetika $7 D000077548
650    _2
$a kolorektální nádory $x diagnóza $x genetika $7 D015179
650    _2
$a metylace DNA $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické testování $x metody $x normy $7 D005820
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $x normy $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a MutL homolog 1 $x nedostatek $x genetika $7 D000070957
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
650    _2
$a tyrosinkinasové receptory $x genetika $7 D020794
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vaněček, Tomáš $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
700    1_
$a Ptáková, Nikola $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic $u Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hájková, Veronika $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
700    1_
$a Dušek, Martin $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
700    1_
$a Michal, Michael $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Švajdler, Peter $u Cytopathos s.r.o, Bratislava, Slovakia
700    1_
$a Daum, Ondřej $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
700    1_
$a Daumová, Magdaléna $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
700    1_
$a Michal, Michal $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
700    1_
$a Mezencev, Roman $u School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA
700    1_
$a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Bioptická Laboratoř, s.r.o, Pilsen, Czech Republic
773    0_
$w MED00001898 $t Genes, chromosomes & cancer $x 1098-2264 $g Roč. 59, č. 10 (2020), s. 562-568
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32427409 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132844 $b ABA008
999    __
$a ok $b bmc $g 1715283 $s 1147019
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 59 $c 10 $d 562-568 $e 20200610 $i 1098-2264 $m Genes, chromosomes & cancer $n Genes Chromosom Cancer $x MED00001898
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace